NovoCure (NVCR) Leerink Global Healthcare Conference 2026 summary

Company overview and strategic focus

• Built on the insight that cancer cells have unique electrical properties, leading to device-based therapies for glioblastoma, non-small cell lung cancer, and pancreatic cancer.

• Recent leadership change emphasizes commercial viability and patient access, shifting focus to indications with strong business potential.

• Prioritizing cancers with low drug bioavailability and those where physical therapies can overcome biological limitations.

• Emphasizing patient motivation and ability to comply with therapy as key factors in indication selection.

• Multi-indication approach leverages existing field force and infrastructure for growth.

Clinical development and growth opportunities

• GBM remains a core market with about 40% penetration and over 4,400 active patients, generating $645 million in 2025 revenue.

• TRIDENT phase 3 trial in newly diagnosed GBM could expand eligible patient population by 25% and extend therapy duration.

• Pancreatic cancer launch targets a TAM of 15,000 patients annually, with strong early demand from patients and physicians.

• PANOVA-4 phase 2 trial in metastatic pancreatic cancer will provide top-line data soon, potentially informing future development.

• Lung cancer growth expected mainly from Japan following reimbursement, with US dynamics stable; further investment depends on commercial viability.

Commercial execution and future outlook

• Double-digit revenue growth anticipated from GBM and pancreatic cancer, with disciplined development in existing indications.

• Leveraging learnings from GBM and lung launches to streamline pancreatic cancer rollout, focusing on ease of prescription and patient support.

• Exploring combination strategies with KRAS inhibitors and immune checkpoint inhibitors, aiming for synergistic effects without added toxicity.

• Patient experience in pancreatic cancer shows minimal added skin irritation and high compliance; protocol adjustments may further improve usability.

• Path to profitability centers on disciplined operating expenses and incremental investment, with infrastructure in place for multi-indication growth.